Hemab Therapeutics

Hemab Therapeutics is a private, clinical-stage biotech focused on addressing the significant unmet need in rare bleeding disorders like Glanzmann Thrombasthenia (GT) and Von Willebrand Disease (VWD). The company has advanced two lead clinical assets, sutacimig (in Phase 2/3 for GT) and HMB-002 (in Phase 1/2 for VWD), with promising data and regulatory support including a Breakthrough Therapy Designation for sutacimig. Backed by a substantial $157 million Series C financing, Hemab is well-positioned to advance its pipeline toward pivotal studies and expand its research into other underserved hemostatic disorders.

Proprietary antibody-based platform engineering bispecific or monoclonal antibodies to precisely modulate clotting proteins, protecting them from degradation, modulating activity, and enabling tissue targeting to restore hemostatic balance.

Hemab operates in a niche with limited direct competition due to the historical neglect of these ultra-rare disorders. However, potential competitors include other biotechs exploring bispecific antibodies for hemostasis or companies developing gene therapies for rare coagulation factor deficiencies. Its primary competition is the current substandard of care.